ArticleProtein science : a publication of the Protein Society2025
Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic remodeling and immunoregulatory functions of the B cell-humoral immunity axis in inflammatory bowel disease.Frontiers in immunology · 2026Review
- Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs) have transformed therapeutic strategies for various diseases. However, administering them can lead to unwanted adverse effects and insufficient delivery to local disease sites. Recent research has shown that substitutions in the immunoglobulin G (IgG) Fc region, designed to eliminate binding to the neonatal Fc receptor (FcRn), which accelerates clearance from systemic circulation, may improve the safety of antibody therapies intended for localized use. A major concern with these substitutions is their ability to impair binding to protein A, which is considered the gold standard for large-scale antibody purification. In this study, we investigated multiple amino acid substitutions at residues I253, H310, H435, and Y436-positions known to affect FcRn or protein A interactions-and found that H435F eliminates FcRn binding while maintaining protein A affinity. Importantly, the H435F substitution resulted in accelerated clearance and a shorter serum half-life in human FcRn transgenic mice. Moreover, purification using protein A chromatography proved to be effective without significantly compromising yield. Overall, these findings highlight the potential of the H435F substitution to optimize the pharmacokinetics of antibody therapeutics for localized use, reducing systemic side effects. This study paves the way for the use of antibody-based therapeutics in localized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.